NASDAQ
27.06.25 | 21:59
1,950 US-Dollar
+5,41 % +0,100
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.06. | TELA Bio, Inc.: TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 117 | GlobeNewswire (Europe) | MALVERN, Pa., June 06, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction... ► Artikel lesen | |
| 03.06. | TELA Bio, Inc.: TELA Bio Announces European Commercial Launch of OviTex Inguinal for Robotic and Laparoscopic Inguinal Hernia Repair | 79 | GlobeNewswire (Europe) | MALVERN, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today... ► Artikel lesen | |
| 02.06. | TELA Bio ernennt Jeffrey Blizard zum neuen Präsidenten | 2 | Investing.com Deutsch | ||
| 02.06. | TELA Bio, Inc.: TELA Bio Appoints Jeffrey Blizard as President | 120 | GlobeNewswire (Europe) | MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today... ► Artikel lesen | |
| 30.05. | TELA Bio, Inc. - 8-K, Current Report | 6 | SEC Filings | ||
| 20.05. | Piper Sandler maintains TELA Bio stock at Neutral with $2 target | 2 | Investing.com | ||
| 09.05. | TELA Bio, Inc.: TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 90 | GlobeNewswire (Europe) | MALVERN, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction... ► Artikel lesen | |
| 09.05. | TELA Bio GAAP EPS of -$0.25 misses by $0.05, revenue of $18.5M beats by $1.15M | 2 | Seeking Alpha | ||
| TELA BIO Aktie jetzt für 0€ handeln | |||||
| 08.05. | TELA Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 17.04. | TELA Bio, Inc.: TELA Bio to Announce First Quarter 2025 Financial Results | 2 | GlobeNewswire (USA) | ||
| 09.04. | Canaccord maintains TELA Bio stock with $7 target post-challenges | 1 | Investing.com | ||
| 31.03. | TELA Bio introduces larger sizes for soft tissue reconstruction | 1 | Investing.com | ||
| 31.03. | TELA Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 31.03. | TELA Bio, Inc.: TELA Bio Announces U.S. Commercial Launch of Larger Sizes of OviTex PRS for Plastic and Reconstructive Surgery | 1 | GlobeNewswire (USA) | ||
| 22.03. | TELA Bio, Inc. (NASDAQ:TELA) Q4 2024 Earnings Call Transcript | 1 | Insider Monkey | ||
| 21.03. | TELA Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 21.03. | TELA Bio, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 21.03. | Tela Bio slumps after Q4 miss as Piper Sandler downgrades | 2 | Seeking Alpha | ||
| 21.03. | Canaccord cuts TELA Bio stock target to $7, maintains Buy | 3 | Investing.com | ||
| 21.03. | TELA Bio stock price target cut to $7 by Citizens JMP | 2 | Investing.com |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MODERNA | 23,305 | +0,17 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 14,575 | -0,21 % | Did The FDA Make A Mistake? Sarepta's Elevidys Approval Under Scrutiny | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,099 | -0,67 % | Beyond The Numbers: 4 Analysts Discuss Pacific Biosciences Stock | ||
| PHIO PHARMACEUTICALS | 2,250 | +1,81 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort | -Phio's lead clinical siRNA compound PH-762 demonstrates supportive safety profile in fourth cohort, permitting dose escalation in expected final cohortMarlborough, Massachusetts--(Newsfile Corp. -... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 2,076 | +7,79 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA (pembrolizumab) in Patients with Metastatic Melanoma | SOUTH SAN FRANCISCO, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that the... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 5,155 | -2,92 % | Vir Biotechnology, Inc.: Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study | HBsAg loss 24 weeks post-end of treatment achieved in 17% and 21% of participants with low baseline HBsAg receiving tobevibart elebsiran without or with PEG-IFNa, respectively As previously... ► Artikel lesen | |
| RAPT THERAPEUTICS | 8,565 | +18,88 % | RAPT Therapeutics adds two new directors to board | ||
| TC BIOPHARM | 0,825 | 0,00 % | TC BioPharm Announces Complete Response in Minimal Residual Disease (MRD) Patient | First patient in Cohort B achieved CR after 2nd dose of TCB008
EDINBURGH, Scotland, June 11, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC (NASDAQ: TCBP)... ► Artikel lesen | |
| SOLID BIOSCIENCES | 4,720 | -1,87 % | Citi startet Berichterstattung für Solid Biosciences mit Kaufempfehlung | ||
| HARMONY BIOSCIENCES | 31,980 | +0,38 % | Mizuho reaffirms Harmony Biosciences stock rating on positive orexin data | ||
| CG ONCOLOGY | 25,950 | -0,46 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
| QIAGEN | 41,000 | -0,56 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
| LYELL IMMUNOPHARMA | 8,940 | -1,97 % | Lyell Immunopharma, Inc. - 8-K, Current Report | ||
| SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc. - 8-K, Current Report | ||
| KYMERA THERAPEUTICS | 44,080 | -3,57 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen |
TELA BIO INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,100 (+5,41 %) liegt der Kurs bei 1,950 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TELA BIO INC finden Sie auf Wallstreet Online.